CELON PHARMA S.A. ZY-10

Research CELON PHARMA S.A. ZY-10 (8RP) on Bullrun: valuation model: 18.8% undervalued, market cap EUR 238.05M, P/E 9.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker8RP
• ExchangeF
• CountryPoland
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Valuation signal18.8% undervalued
• Market capEUR 238.05M
• P/E9.2
• Financial periodQ4 2025
• Net income-EUR 24.90M
• Free cash flowEUR 64.59M

Valuation Snapshot

Bullrun's latest valuation model marks CELON PHARMA S.A. ZY-10 as 18.8% undervalued; latest market cap is EUR 238.05M; P/E is 9.2.

About CELON PHARMA S.A. ZY-10

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

Frequently asked questions

Is CELON PHARMA S.A. ZY-10 overvalued or undervalued?

Bullrun's valuation model currently marks CELON PHARMA S.A. ZY-10 as 18.8% undervalued.

What is CELON PHARMA S.A. ZY-10's market cap?

CELON PHARMA S.A. ZY-10's market capitalization is EUR 238.05M.

What is CELON PHARMA S.A. ZY-10's P/E ratio?

CELON PHARMA S.A. ZY-10's price-to-earnings (P/E) ratio is 9.2.

What does CELON PHARMA S.A. ZY-10 do?

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A.